Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

187 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-25

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 2 diabetes is rapidly increasing globally and has been associated with an increased risk of colorectal cancer. Therefore, the numbers of diabetic patients who will undergo colonoscopic screening are expected to grow exponentially. Colonoscopic preparation entails prolonged fasting, cessation of anti-diabetic medication and ingestion of preparation medications. This may put the diabetic patient at risk of potentially dangerous hypo- or hyperglycemia. However, studies regarding the safety of colonoscopic preparation in diabetic are lacking. In this study, the investigators aim to discover the prevalence of abnormal glucose levels in diabetic patients who undergo colonoscopy. The investigators also aim to find out risk factors for abnormal glucose levels and develop a safe preparation protocol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Split Dose of Low-volume Polyethylene Glycol on Adenoma Detection Rate

NCT02178033

Colonic Adenomas

UNKNOWN NA

A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods

NCT02250196

Colorectal Cancer Colon Adenoma

COMPLETED PHASE3

Effect of Single Dose of 2L PEG on Bowel Preparation in Average-risk Patients Undergoing Colonoscopy

NCT02998255

Health Behavior

COMPLETED NA

Second Bowel Preparation for Colonoscopy Failure

NCT01510977

Colonoscopy Failure Poor Bowel Preparation

TERMINATED PHASE4

Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation

NCT03356015

Bowel Preparation Scale Adenoma Detection Rate

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Type 2 diabetes subjects who will undergo colonoscopy will be prospectively enrolled when visiting the outpatient clinic.
2. Subjects will be instructed to fast from 6pm of the day before colonoscopy.
3. Subjects will be instructed to abstain from diabetes medication while the subjects fast.
4. Subjects who are scheduled to undergo colonoscopy in the morning will take colonoscopy preparation medication (2L (liter) of polyethylene glycol with ascorbic acid) in a split dose (i.e. 1L from 8-10 pm of the day before colonoscopy and 1L 4-6 hours before colonoscopy). Those who will undergo colonoscopy in the afternoon will take 2L of the preparation medication 6 hours before colonoscopy.
5. Subjects will be instructed to take the preparation medication at rate of 250 mL every 10 to 15 minutes.
6. Upon arrival at the endoscopy center of International St. Mary's hospital, subjects will be given a self-administered questionnaire which will ask about their age, gender, duration of diabetes, type of diabetes medication, time of last diabetes medication taken, knowledge of hypo/hyperglycemia symptoms, previous hypo/hyperglycemia experience, self-treatment of hypoglycemia (if done), total amount of colonoscopy preparation medication ingested, total fasting time and time of last preparation medication ingested.
7. Subjects will have vital signs (blood pressure, heart rate) taken and their capillary glucose levels checked using the Accu-Chek Performa.
8. Any subjects with capillary glucose levels \<70mg/dL or \>250mg/dL will be reported to the attending physician. Those with an initial glucose level \<70mg/dL will be given a piece of candy and have their glucose rechecked in 10 mins. Subjects will be asked if the hypoglycemic symptoms (if any) have abated. Those with a glucose level \>250mg/dL will undergo hydration with normal saline at 120 ml/Hr. Those who do not respond to treatment or are in critical condition will be moved to the Emergency department for treatment. Subjects who respond to treatment will have their glucose levels checked after colonoscopy before undergoing discharge. Those with abnormal levels upon follow-up testing will be sent to either the endocrinology outpatient clinic or the emergency room depending on their clinical severity.
9. All data will be recorded by initials with patient identities masked. All data will be kept in a locked and secure location by the principal investigator.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Colonoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single group

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetes group

Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.

Group Type OTHER

Colonoscopy preparation using polyethylene glycol

Intervention Type DRUG

Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colonoscopy preparation using polyethylene glycol

Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Have not taken diabetes medication since 6pm of the day before colonoscopy. Have fasted since 6pm of the day before colonoscopy.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes
* Between ages of 20-75
* Undergo colonoscopy at International St. Mary's Hospital

Exclusion Criteria

* Type 1 diabetes patients
* Did not undergo colonoscopy preparation
* Did not meet fasting requirements
* Have known current infectious diseases
* Have known cancer and/or are under cancer treatment
* Are under intravenous fluid therapy during colonoscopy

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes